Neumora Therapeutics, Inc. (NMRA) Income Statement
NMRA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNMRA revenue and net income
NMRA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NMRA quarterly EPS vs estimates
Neumora Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.19).
NMRA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $5.0M | — | $668,000 | $2.7M | $1.6M | — |
| Gross profit | −$5.0M | — | −$668,000 | −$2.7M | −$1.6M | — |
| Research & development | $176.1M | $200.9M | $142.7M | $104.7M | $212.8M | $87.1M |
| Sales, general & admin | $60.1M | $62.5M | $46.1M | $31.1M | $24.5M | $8.4M |
| Total operating expenses | $236.2M | $263.5M | $187.5M | $135.9M | $237.3M | $95.5M |
| Operating income | −$241.2M | −$263.5M | −$188.2M | −$135.9M | −$237.3M | −$95.5M |
| Interest income | $8.3M | $19.9M | $16.6M | $4.6M | $0 | — |
| Interest expense | $3.2M | — | — | — | — | — |
| Income before taxes | −$236.8M | −$243.6M | −$235.7M | −$130.9M | −$237.3M | −$99.3M |
| Income taxes | $130,000 | $178,000 | $268,000 | −$4.6M | $301,442 | −$101,297 |
| Net income | −$236.9M | −$243.8M | −$235.9M | −$130.9M | −$237.3M | −$99.3M |
| EBITDA | −$233.4M | −$243.0M | −$235.0M | −$130.3M | −$236.8M | −$95.4M |
| EPS (diluted) | −$1.45 | −$1.53 | −$2.13 | −$0.86 | −$1.56 | −$0.65 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $8,000 | — | $5.0M | — | — | $318,000 | — | $160,000 | $158,000 | $166,000 | $1.0M |
| Gross profit | — | −$8,000 | — | −$5.0M | — | — | −$318,000 | — | −$160,000 | −$158,000 | −$166,000 | −$1.0M |
| Research & development | $29.3M | $38.6M | $44.7M | $40.5M | $38.7M | $52.2M | $45.9M | $60.6M | $48.6M | $45.8M | $38.9M | $41.6M |
| Sales, general & admin | $12.9M | $14.3M | $13.8M | $12.2M | $15.3M | $18.8M | $17.0M | $16.0M | $15.4M | $14.3M | $11.2M | $15.3M |
| Total operating expenses | $42.2M | $52.9M | $58.5M | $52.7M | $54.0M | $70.9M | $62.9M | $76.6M | $63.8M | $60.1M | $49.9M | $56.9M |
| Operating income | −$42.2M | −$52.9M | −$58.5M | −$57.7M | −$54.0M | −$70.9M | −$62.9M | −$76.6M | −$63.8M | −$60.1M | −$50.1M | −$56.9M |
| Interest income | $935,000 | $1.2M | $1.3M | $1.7M | $1.8M | $3.1M | $4.1M | $4.2M | $5.3M | $6.4M | $5.6M | $3.8M |
| Interest expense | $1.8M | $1.9M | $2.0M | $747,000 | $436,000 | $0 | — | — | — | — | — | — |
| Income before taxes | −$43.1M | −$53.4M | −$59.5M | −$56.8M | −$52.7M | −$67.9M | −$58.8M | −$72.5M | −$58.6M | −$53.7M | −$108.5M | −$53.0M |
| Income taxes | — | $30,000 | — | — | $25,000 | $105,000 | — | $53,000 | $125,000 | −$6.4M | $268,000 | −$4.0M |
| Net income | −$43.1M | −$53.5M | −$59.5M | −$56.8M | −$52.7M | −$68.0M | −$58.8M | −$72.5M | −$58.7M | −$53.7M | −$108.7M | −$53.0M |
| EBITDA | −$42.2M | −$51.6M | −$57.4M | −$56.0M | −$52.7M | −$67.7M | −$58.7M | −$72.3M | −$58.4M | −$53.6M | −$108.3M | −$52.9M |
| EPS (diluted) | −$0.23 | −$0.30 | −$0.35 | −$0.35 | −$0.33 | −$0.42 | −$0.37 | −$0.45 | −$0.37 | −$0.34 | −$0.71 | −$1.14 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NMRA's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NMRA financial results
Neumora Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $236.9 million. Diluted earnings per share came to −$1.45.
See the NMRA stock overview for the latest quote and news, or the NMRA chart for price history and technical indicators.
NMRA income statement FAQ
Does Neumora Therapeutics have revenue?
Neumora Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Neumora Therapeutics profitable?
No. Neumora Therapeutics reported a net loss of $236.9 million in fiscal 2025.
How much does Neumora Therapeutics spend on research and development?
Neumora Therapeutics spent $176.1 million on research and development in fiscal 2025.
What are Neumora Therapeutics's earnings per share?
Neumora Therapeutics earned $-1.45 per diluted share in fiscal 2025, compared with $-1.53 a year earlier.
When will Neumora Therapeutics report its next earnings?
Neumora Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Neumora Therapeutics's fiscal year end?
Neumora Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.